Navigation Links
INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray
Date:3/8/2010

Dr. Richard Rauck, a principal investigator in the Phase III study observed, "The sublingual spray demonstrated very rapid, effective pain relief. Patients began to experience meaningful pain relief within five minutes. This observation was supported by the clinical research findings.  To date, no other transmucosal Fentanyl product has produced pain relief this quickly. This early finding is supported with continued pain relief at all subsequent time intervals.  An easy-to-use oral spray that can produce effective, potent and very rapid pain relief will be a tremendous advantage for our patients who experience moderate to severe cancer breakthrough pain."

Michael Babich, President and COO of INSYS, adds, "We are delighted to announce today's results as it validates our thesis that a delivery system that can be administered in seconds will be a benefit to patients suffering from this indication.  More importantly, the results seen at five minutes will benefit patients and doctors who may struggle to find a product that can work quickly as breakthrough pain's onset is quite rapid.  In addition, many patients may not be able to take other currently available drugs due to difficulty in swallowing, nausea or other gastrointestinal problems.  Our device and array of strengths (100 to 1600 mcg) will allow patients to be treated at their appropriate titrated level.  Finally, we were excited to see that 97% of the patients randomized to the double blind period completed the study, while 92% rolled over to the safety portion."


'/>"/>
SOURCE INSYS Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
10. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 ... successfully used to save millions of lives across globe. ... the Kingdom of Saudi Arabia . ... raw material suppliers, government agencies and regulatory bodies. The ... been studied from two perspectives: by products and by ...
(Date:9/3/2015)... Sept. 3, 2015  WellCare Health Plans, Inc. (NYSE: ... , senior vice president and chief financial officer, is ... Healthcare Conference on Wednesday, September 9, 2015, at 9:25 ... webcast live. In addition, a replay of the webcast ... broadcast. Both the live broadcast and the replay will ...
(Date:9/3/2015)... RICHMOND, Va. , Sept. 3, 2015  As ... for patients with heart disease, Marc R. Katz ... of the Bon Secours Heart & Vascular Institute implanted ... August 18, 2015. The patient was selected as part ... is one of 60 elite centers in the United ...
Breaking Medicine Technology:Saudi Arabia Defibrillators Market: & Advanced Life Support Defibrillators; End Users; Industry Analysis, Size, Volume, Growth, Trends and Forecast 2014 - 2020 2Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 2Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 3Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 4
... BERGISCH GLADBACH, Germany, May 20 Miltenyi ... Myelin Removal Beads. Myelin,is a specialized membrane ... and central nervous system. During preparation of ... contaminant. "When,dissociating adult neural tissue, usually less ...
... New data demonstrate that maintenance therapy with RISPERDAL(R) CONSTA(R) ... relapse compared to placebo in patients with Bipolar I ... at a major medical meeting. Bipolar Disorder is ... person,s mood, energy and ability to function. It is ...
Cached Medicine Technology:Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
(Date:9/3/2015)... ... 03, 2015 , ... BedJet released a new version of its award winning ... Today the BedJet v2 pre-order campaign blazed past the $1 million dollar ... ever on crowdfunding giant Kickstarter. , Simple to use and beautifully designed, the award ...
(Date:9/3/2015)... ... September 03, 2015 , ... Real Time Pain Relief (RTPR), ... bull rider David Mason has signed an official endorsement deal with the company. Originally ... six and his first bull at 15. He is an Australian bull riding champion, ...
(Date:9/3/2015)... ... 2015 , ... Hope For The Warriors® is pleased to ... awarded two times each year to spouses or caregivers of post-9/11 wounded or ... restoring a sense of self, restoring the family unit, and restoring hope for ...
(Date:9/3/2015)... GA (PRWEB) , ... September 03, 2015 , ... ... cover the cost of graduated compression garments. However, graduated compression garments are an ... Wound care and lymphedema specialist, Robyn Bjork, was recently sponsored by SIGVARIS ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... landscape by connecting accredited and institutional investors to real estate investment opportunities nationwide, ... to meet demand from both investors and sponsoring real estate companies. ...
Breaking Medicine News(10 mins):Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 3Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 3Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 3Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3
... taken necessary steps and planned a schedule to support employed ... that women took leave from work very often to take ... schedule of work and increased their stress level. ... wide rage of medical problems. The news paper said that ...
... medical marijuana, concerns have been raised by justices regarding allowing ... symptoms and perhaps even prolong life. A federal appeals court ... legal wrangling over the issue, this week. ,The ... the drug should be allowed, it is the only viable ...
... Statistics show that about one in 100 11-year-olds had taken ... and one in 10 of 15-year-olds// have taken hard drugs. ... pupils. They take illegal drugs such as cocaine which has ... , The survey was carried out among England's 3.4 million ...
... getting sensitive to noise, and do not like it much! ... noisy surroundings// may face an increased risk of suffering a ... chances of urban middle-aged adults, living on high-traffic ... percent chance of suffering heart attack, than those who lived ...
... Even though mental disorders are said to account for ... studies have been undertaken to assess// this assumption in ... as part of the WHO World Mental Health (WMH) ... 2857 adults was done in Lebanon between September, 2002, ...
... The new low nicotine Quest? cigarettes seems to have ... to a study conducted by researchers// at the Transdisciplinary ... School of Medicine.Results of the study have been published ... ,The author of this study, Caryn Lerman, PhD, Associate ...
Cached Medicine News:Health News:Cancer Patient to Appeal to SC, Demanding Right to Use Marijuana 2Health News:A National Survey Revealed That Mental Disorders Are Common In Lebanon 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: